Literature DB >> 30093938

Prognosis of patients with TX stage differentiated thyroid cancer: propensity scored matching analysis of the SEER database 2004-2013.

Yiquan Xiong1, Qiuyang Zhao1, Chunping Liu1, Shuntao Wang1, Zeming Liu1, Tao Huang1.   

Abstract

In differentiated thyroid cancer (DTC), TX stage is defined as 'primary tumour cannot be assessed'. The prognosis of patients with TX stage remains unclear. The aim of this study was to investigate the prognosis of TX stage and provide a perspective on treatment guidelines. We investigated a large cohort of DTC patients from the Surveillance, Epidemiology, and End Results database between 2004 and 2013. Patient mortality was examined by Kaplan-Meier analyses with log-rank tests and Cox proportional hazards regression analyses. The rate of cancer-specific mortality per 1000 person-years for patients with TX stage was higher than for patients with T1-T3 stage, but lower than for patients with T4 stage. The all-cause mortality per 1000 person-years for TX stage patients was also higher than for T1-T3 stage patients, but lower than for T4 stage patients. TX stage showed significant risk for cancer-specific mortality compared to T1 and T4 stages, but not T2 and T3 stages, after adjusting for influential risk factors. TX stage patients showed no significant risk for all-cause mortality compared to T2-T3 stage patients, but were different than T1 and T4 stage patients. These results provide new implications for the treatment of TX stage DTC patients.

Entities:  

Keywords:  Differentiated thyroid cancer; SEER; TX stage; prognosis

Year:  2018        PMID: 30093938      PMCID: PMC6079136     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  18 in total

Review 1.  Cancers with increasing incidence trends in the United States: 1999 through 2008.

Authors:  Edgar P Simard; Elizabeth M Ward; Rebecca Siegel; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

2.  Recent incidences and differential trends of thyroid cancer in the USA.

Authors:  Yushan Mao; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2016-02-25       Impact factor: 5.678

Review 3.  Thyroid cancer.

Authors:  Maria E Cabanillas; David G McFadden; Cosimo Durante
Journal:  Lancet       Date:  2016-05-27       Impact factor: 79.321

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 5.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

6.  Papillary thyroid microcarcinoma: an over-treated malignancy?

Authors:  Tracy S Wang; Paolo Goffredo; Julie Ann Sosa; Sanziana A Roman
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

7.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

8.  Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality.

Authors:  Rengyun Liu; Justin Bishop; Guangwu Zhu; Tao Zhang; Paul W Ladenson; Mingzhao Xing
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

9.  Long-Term Follow-Up of the Therapeutic Outcomes for Papillary Thyroid Carcinoma With Distant Metastasis.

Authors:  Jen-Der Lin; Chuen Hsueh; Tzu-Chieh Chao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

10.  Diagnostic accuracy of ultrasonographic features for lymph node metastasis in papillary thyroid microcarcinoma: a single-center retrospective study.

Authors:  Zeming Liu; Wen Zeng; Chunping Liu; Shuntao Wang; Yiquan Xiong; Yawen Guo; Xiaoyu Li; Shiran Sun; Tianwen Chen; Yusufu Maimaiti; Pan Yu; Tao Huang
Journal:  World J Surg Oncol       Date:  2017-01-26       Impact factor: 2.754

View more
  4 in total

1.  Clinical roles of miR-136-5p and its target metadherin in thyroid carcinoma.

Authors:  Rui-Zhi Gao; Qiao Que; Peng Lin; Yu-Yan Pang; Hua-Yu Wu; Xiao-Jiao Li; Gang Chen; Yun He; Hong Yang
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

2.  Innovative analysis of distant metastasis in differentiated thyroid cancer.

Authors:  Danyang Chen; Lei Huang; Sichao Chen; Yihui Huang; Di Hu; Wen Zeng; Min Wang; Wei Zhou; Haifeng Feng; Wei Wei; Chao Zhang; Zeming Liu; Liang Guo
Journal:  Oncol Lett       Date:  2020-01-15       Impact factor: 2.967

3.  Synergic effects of histology subtype, tumor size, and lymph node metastasis on distant metastasis in differentiated thyroid cancer.

Authors:  Zeming Liu; Sichao Chen; Yihui Huang; Di Hu; Wen Zeng; Min Wang; Wei Zhou; Danyang Chen; Haifeng Feng; Wei Wei; Chao Zhang; Ling Zhou; Liang Guo
Journal:  Ann Transl Med       Date:  2019-10

4.  Blood prognostic predictors of treatment response for patients with papillary thyroid cancer.

Authors:  Xiangxiang Liu; Zhongke Huang; Xianghui He; Xiangqian Zheng; Qiang Jia; Jian Tan; Yaguang Fan; Cen Lou; Zhaowei Meng
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.